Caitong International Asset Management’s Contineum Therapeutics CTNM Stock Holding History

Caitong International Asset Management’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13	Buy	+1	New	+$13	﹤0.01%	2117

Other funds holding CTNM

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Caitong International Asset Management's CTNM Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Contineum Therapeutics (CTNM) in Q1 2026: 1 share worth $13. The stake represents ﹤0.01% of the portfolio and ranks #2117 among its holdings.

90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

Caitong International Asset Management held 1 share of Contineum Therapeutics worth $13 as of Q1 2026.
Contineum Therapeutics was a new Caitong International Asset Management position in Q1 2026.
Contineum Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2117 holding.
90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.